Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.

Cellectis scraps CAR-T pipeline in gene editing pivot - European Biotechnology Magazine

French biotech Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease.

Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript

Operator Good morning, ladies and gentlemen. Welcome to the Cellectis Live conference call, English session. [Operator Instructions] This call is being recorded on Monday, September 14, 2026. I would now like to turn the conference over to Arthur Stril, CFO and CBO. Please go ahead. Arthur StrilCFO & Chief Business Officer Good morning, everyone, and [...]

Cellectis Transforming Into In Vivo Gene Editing Company

Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.